After the summer holidays, we return to the Project with a consortium meeting to catch up on the latest results obtained in each work group and coordinate future activities. Thanks to the start-up of the Computational Microscopy Unit, we have been able to screen in silico more than 180 million compounds! In addition, molecular dynamics studies have allowed us to predict which of the most promising compounds have the highest binding affinity and stability with NRF2. The next phase, which we have already begun, will be to experimentally check the properties of the selected compounds. It involves performing in vitro screening through preclinical studies of toxicity, NRF2 induction, neuroprotection, and blood brain barrier penetration, among others, using both cellular and mouse models.